Nuevocor Appoints Dr. Monica Shah as Chief Medical Officer
**media[1033300]**SINGAPORE, PARIS and PHILADELPHIA, April 28, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company developing novel therapies for patients suffering from life-threatening cardiomyopathies, today announced the appointment of Monica Shah, MD, FACC, as Chief Medical Officer. Dr. Shah will lead the Company's global clinical development and medical affairs at an inflection point as Nuevocor prepares to initiate a first-in-human clinical study of NVC-001 in patients with LMNA-associated dilated cardiomyopathy (DCM), one of the most aggressive forms of genetic heart disease. A board-certified heart failure and transplant cardiologist, Dr. Shah brings more than two decades of experience in cardiovascular medicine and drug development across academia, NIH, and industry, including leadership roles in both biotech and CRO organizations. Most recently, she served as Chief Medical Officer of CTI Clinical Trial & Consulting, a specialty CRO, where she oversaw medical strategy across a broad portfolio of complex clinical programs spanning rare disease, gene therapy, and cardiovascular indications. Prior to CTI, she was Senior Vice President and AAV Global Program Head at Rocket Pharmaceuticals, where she launched and led pivotal clinical programs in cardiovascular gene therapy. She previously served as Vice President and Global Head of Cell and Gene Therapy at IQVIA, leading the company's multidisciplinary CGT Center of Excellence and partnering with sponsors to advance programs from early clinical development through commercialization. Earlier in her career, Dr. Shah spent nearly a decade at the National Institutes of Health, serving as Deputy Chief of Heart Failure and Arrhythmias at the National Heart, Lung, and Blood Institute and Director of the Trial Innovation Network at the National Center for Advancing Translational Sciences.
